enGene

enGene is a clinical-stage genetic medicines company focused on developing non-viral gene therapies for underserved diseases. Their proprietary Dually Derivatized Oligochitosan (DDX) platform enables localized delivery of gene cargos directly to mucosal tissues, potentially overcoming limitations of viral-based gene therapies. This technology offers a unique approach to treating a wide range of diseases, including non-muscle invasive bladder cancer (NMIBC), where conventional therapies often have limited efficacy or significant side effects.

enGene's lead program, detalimogene voraplasmid, is a non-viral gene therapy designed to elicit a local immune response in the bladder. This approach has the potential to improve the standard of care for patients with BCG-resistant NMIBC, providing a safer and more effective alternative to bladder removal. enGene is actively advancing its clinical development pipeline, pursuing potential applications for their DDX platform across various therapeutic areas.

enGene does not mention any information about the company's job flexibility on their website or in the job posting.

enGene is a clinical-stage genetic medicines company focused on developing practical and life-changing non-viral therapies for patients with underserved diseases, particularly those affecting mucosal tissues. Their groundbreaking Dually Derivatized Oligochitosan (DDX) platform delivers multiple gene cargos directly to mucosal tissues, potentially overcoming the limitations of viral-based gene therapies and expanding gene therapy beyond rare diseases into mainstream clinical practice. enGene is committed to advancing genetic medicine and improving the lives of patients by developing safe and effective treatments that address unmet medical needs.

enGene cultivates a culture driven by a bold commitment to patient needs, fostering a collaborative environment where fearless innovation and scientific rigor are paramount. They prioritize a team of industry leaders and innovators who are deeply committed to developing practical yet life-changing therapies for underserved diseases, creating a workplace that values ambition, teamwork, and a strong sense of purpose.